The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 16.50
Bid: 16.00
Ask: 17.00
Change: 0.00 (0.00%)
Spread: 1.00 (6.25%)
Open: 16.50
High: 16.50
Low: 16.50
Prev. Close: 16.50
RENX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

30 Apr 2024 07:00

RNS Number : 4878M
Renalytix PLC
30 April 2024
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

Renalytix plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

CVI Investments, Inc.

City and country of registered office (if applicable)

Bala Cynwyd, PA, USA

4. Full name of shareholder(s) (if different from 3.) v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached vi:

26/04/2024

6. Date on which issuer notified (DD/MM/YYYY):

29/04/2024

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

5.10%

0%

5.10%

7,866,882

Position of previous notification (if

applicable)

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BYWL4Y04

7,866,882

0.00%

5.10%

0.00%

SUBTOTAL 8. A

7,866,882

5.10%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

CVI Holdings, LLC.

CVI Investments, Inc.

5.10%

0%

5.10%

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information xvi

 

Place of completion

401 City Ave Suite 220, Bala Cynwyd, PA 19004

Date of completion

29/04/2024

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFLFVDSFIAFIS
Date   Source Headline
9th Nov 20224:35 pmRNSPrice Monitoring Extension
3rd Nov 20227:00 amRNSRENX to Present at Stifel Healthcare Conference
31st Oct 20224:41 pmRNSSecond Price Monitoring Extn
31st Oct 20224:36 pmRNSPrice Monitoring Extension
31st Oct 20227:00 amRNSRenalytix Reports Full Year Fiscal 2022 Results
26th Oct 20229:05 amRNSSecond Price Monitoring Extn
26th Oct 20229:00 amRNSPrice Monitoring Extension
25th Oct 20227:00 amRNSKidneyIntelX Medicare Update
24th Oct 20227:00 amRNSNotice of Results
17th Oct 20227:00 amRNSPresentations accepte at ASN Kiney Week
17th Oct 20227:00 amRNSPresentations accepted at ASN Kidney Week
20th Sep 20227:50 amRNSDirectorate Change
12th Sep 20227:00 amRNSIssue of shares
8th Sep 20227:00 amRNSRenalytix to Present at H.C. Wainwright Conference
17th Aug 202212:00 pmRNSBusiness update
8th Aug 20227:00 amRNSPublication of clinical utility study in The AJMC
30th Jun 20227:00 amRNSRenalytix Reports Financial Results for Q3 of FY22
23rd Jun 20227:00 amRNSRenalytix to Report Financial Results for Q3
10th Jun 20227:00 amRNSMount Sinai clinical utility data
8th Jun 20227:00 amRNSRenalytix to Present at Growth Stock Conference
6th Jun 20227:00 amRNSData Presentations at ADA 82nd Scientific Sessions
6th Jun 20227:00 amRNSKidneyIntelX data shows ability to assess risk
29th Apr 20224:46 pmRNSTotal Voting Rights
22nd Apr 20227:00 amRNSGrant of Share Options
8th Apr 20227:00 amRNSSuccessful completion of $30.0m financing package
8th Apr 20227:00 amRNSIssue of shares
31st Mar 20227:05 amRNS$30.0 million financing package
31st Mar 20227:00 amRNSHalf-year Report
30th Mar 20227:00 amRNSTimothy Scannell appointed to the Board
29th Mar 20227:00 amRNSEnrollment Milestone for KidneyIntelX
25th Mar 20227:00 amRNSNotice of Results
9th Mar 20227:00 amRNSRenalytix Launches myIntelX
24th Feb 20227:00 amRNSPresentation of new clinical data for KidneyIntelX
22nd Feb 20227:01 amRNSRENX to Present at Cowen 42nd Annual Conference
22nd Feb 20227:00 amRNSTimothy Scannell to be appointed to board
27th Jan 20223:19 pmRNSGrant of Share Options
27th Jan 20227:00 amRNSConference attendance
11th Jan 20221:06 pmRNSPositive Study Results Published for KidneyIntelX
10th Jan 20227:00 amRNSPartnership with Singing River for KidneyIntelX
7th Jan 20227:00 amRNSAppointment of Jean M. Casner as CHRO
5th Jan 20227:00 amRNSRENX to present at 40th JP Morgan Healthcare Conf.
4th Jan 20227:00 amRNSJoint program with American Diabetes Association
17th Dec 20213:38 pmRNSResult of AGM
17th Dec 202111:26 amRNSDirector/PDMR Shareholding
13th Dec 20217:00 amRNSDirector/PDMR Shareholding
9th Dec 20217:00 amRNSDirector/PDMR Shareholding
8th Dec 20217:00 amRNSDirector/PDMR Shareholding
7th Dec 20217:00 amRNSRenalytix Reports Financial Results for Q1 of FY22
2nd Dec 20217:00 amRNSNotice of Q1 FY22 Results
19th Nov 20214:43 pmRNSPublication of Annual Report 2021 & Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.